Breakout Discussions

Tuesday, 20 June | 10:10 – 11:10 Breakout Discussions with Coffee Break

The Role of Immune Cells Shaping the TME
Steven Katz, MD, CMO, TriSalus Life Sciences

Are immune cells programmed distinctly in different organs?
Cross talk between suppressive myeloid cells and CAR-T cells
Combinatorial approaches to create a more favorable TME for CAR-T cells

Inflaming the TME Using Oncolytic Viruses
Faith N Howard, PhD, Postdoc Researcher, Oncology & Metabolism, University of Sheffield

Can viruses "go it alone" or are they "the opening act"?
Intravenous vs intratumoural delivery - Targeted intravenous delivery of cancer killing viruses is a viable treatment strategy for hard to reach, immunologically cold tumours?
Beyond liposomes - platforms for oncolytic virus delivery
Clinical translation of nanomedicines

Strategies for Engineering of Gamma Delta T Cell Constructs
Mariolina Salio, MD, Director, Experimental Immunology, Immunocore
H. Trent Spencer, PhD, President, Expression Therapeutics

Use of gene editing technology
Engineering of gamma delta-based TCRs
Creation of gamma delta fusion constructs

Thursday, 22 June | 12:05 – 13:05 Breakout Discussions with Hosted Luncheon

Novel Engineered CAR T Cells for Solid Tumors
Paul Neeson, PhD, Associate Professor, Cancer Immunology Research, Peter MacCallum Cancer Centre

Features of the TME which are hostile to CAR-T cell efficacy
Strategies for engineering CARs to address the solid tumour TME hurdles
Combination treatments with novel CARs - chemotherapy, radiotherapy, oncolytic virus

Successes and Failures in Combination Therapies
Marc A. van Dijk, PhD, CTO, MiNK Therapeutics, Inc.